ORLANDO, Fla., March 30 (Reuters) - AstraZeneca Plc’s (AZN.L) cholesterol-lowering drug Crestor failed to significantly reduce heart problems and death among dialysis patients, researchers said on Monday. The results of the Aurora study dampened hopes for reducing heart risks in patients with serious renal disease, who are vulnerable to cardiovascular problems.
